Davis Investment Partners LLC Sells 1,724 Shares of Amgen Inc. $AMGN

Davis Investment Partners LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 37.5% in the 3rd quarter, Holdings Channel reports. The firm owned 2,876 shares of the medical research company’s stock after selling 1,724 shares during the quarter. Davis Investment Partners LLC’s holdings in Amgen were worth $1,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Illinois Municipal Retirement Fund lifted its stake in Amgen by 3.8% during the third quarter. Illinois Municipal Retirement Fund now owns 60,996 shares of the medical research company’s stock worth $25,710,000 after purchasing an additional 2,230 shares during the period. Confluence Wealth Services Inc. boosted its holdings in Amgen by 7.8% during the third quarter. Confluence Wealth Services Inc. now owns 18,976 shares of the medical research company’s stock valued at $7,998,000 after purchasing an additional 1,376 shares in the last quarter. Moneco Advisors LLC grew its stake in shares of Amgen by 5.5% in the 3rd quarter. Moneco Advisors LLC now owns 4,643 shares of the medical research company’s stock valued at $1,957,000 after purchasing an additional 242 shares during the period. Mesirow Financial Investment Management Inc. grew its stake in shares of Amgen by 2.3% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 14,846 shares of the medical research company’s stock valued at $6,258,000 after purchasing an additional 328 shares during the period. Finally, Woodley Farra Manion Portfolio Management Inc. grew its stake in shares of Amgen by 4.1% in the 3rd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 15,509 shares of the medical research company’s stock valued at $6,537,000 after purchasing an additional 613 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMGN. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Cantor Fitzgerald boosted their price target on Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. Bank of America upped their price target on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Oppenheimer reiterated an “outperform” rating on shares of Amgen in a research note on Friday, October 23rd. Finally, Piper Sandler lifted their price objective on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $422.76.

Amgen Stock Performance

NASDAQ AMGN opened at $465.23 on Wednesday. The firm has a market cap of $251.65 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 3.25 and a beta of 0.43. The company has a 50 day moving average of $423.79 and a 200-day moving average of $379.39. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.64 earnings per share. On average, equities analysts forecast that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is currently 58.47%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.